Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.88 |
| ▸ | BLM | P54132 | 3/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | TSHR | P16473 | 3/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.88 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | HTR2A | P28223 | 2/20 | 0.88 |
| ▸ | HTR2C | P28335 | 2/20 | 0.88 |
| ▸ | HTR2B | P41595 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | HTR7 | P34969 | 1/20 | 0.88 |
| ▸ | MTOR | P42345 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxitriptan SCHEMBL7721883 | 1.00 | KMT2A (0.88) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL2721519 | 1.00 | KMT2A (0.88) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL5921917 | 1.00 | KMT2A (0.88) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL30209795 | 1.00 | KMT2A (0.88) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL43242 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL1421238 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL21114382 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL21114383 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL3033706 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA | |
| Oxitriptan SCHEMBL19871232 | 0.94 | NPSR1 (1.00) | KMT2ABLMKDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149410-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH THYROID HORMONE | SCOTT III LINZY O (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115916177-A | Treatment of thyroid hormone-related disorders | 林茨·O·斯科特三世 | 2023-04-04 | — | — | CN | disclosed |
| EP-4138809-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH THYROID HORMONE | Scott III, Linzy O. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021216896-A1 | TREATMENT OF CONDITIONS ASSOCIATED WITH THYROID HORMONE | SCOTT LINZY O (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20180318258-A1 | Molecules in the Tryptophan-5-Hydroxytryptophan-Serotonin-NAS-Melatonin/6-Hydroxymelatonin Sulfate-Melatonin Receptor 1A pathway in Neurological Diseases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180136233-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9891235-B2 | Pathway specific assays for predicting irritable bowel syndrome diagnosis | NESTEC S.A. (CH) | 2018-02-13 | — | — | US | disclosed |
| CN-107257805-A | Antibody of antiserotonin, tryptophan and kynurenine metabolites and application thereof | 雀巢产品技术援助有限公司 | 2017-10-17 | — | — | CN | disclosed |
| EP-3221353-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | Nestec S.A. (CH) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079708-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2016-05-26 | — | — | WO | disclosed |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
| EP-3004068-A2 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | Nestec S.A. (CH) | 2016-04-13 | — | — | EP | disclosed |
| EP-2028935-A2 | ADMINISTRATION OF DOPA PRECURSORS WITH SOURCES OF DOPA TO EFFECTUATE OPTIMAL CATECHOLAMINE NEUROTRANSMITTER OUTCOMES | Neuroresearch, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146174-A2 | ADMINISTRATION OF DOPA PRECURSORS WITH SOURCES OF DOPA TO EFFECTUATE OPTIMAL CATECHOLAMINE NEUROTRANSMITTER OUTCOMES | NEURORESEARCH, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-5110797-A | Neurotropic agents | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0074909-A1 | Compositions on the basis of 5-hydroxy-tryptophane, manufacturing process and medicaments containing them | S.A. PANMEDICA Société dite: (FR) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318258-A1 | Molecules in the Tryptophan-5-Hydroxytryptophan-Serotonin-NAS-Melatonin/6-Hydroxymelatonin Sulfate-Melatonin Receptor 1A pathway in Neurological Diseases | HTR1A, HTR6, HTR5A | KMT2A 2184/4885BLM 4376/4885KDM4E 4328/4885 |
| US-20180136233-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | KMT2A 3586/4885BLM 3119/4885KDM4E 4546/4885 |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | KMT2A 3586/4885BLM 3119/4885KDM4E 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.